[Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology].
Levofloxacin (LVFX, DR-3355), a new synthetic quinolone derivative antibacterial agent, was evaluated for its pharmacokinetics and clinical efficacy in obstetric and gynecological infections, and the following results were obtained. Concentrations of LVFX in serum and intrapelvic genital organs such as uterine and adnexal tissues were determined following oral administration of 100 mg. Tissue penetration of LVFX was found to be good, with its tissue levels (Cmax) of 1.17-2.16 micrograms/ml or g after inhalation anaesthesia and 1.15-2.17 micrograms/ml or g after lumbar spinal anaesthesia. LVFX was given to 22 cases of obstetric and gynecological infections with a daily dose of 200-600 mg for 3-14 days and its clinical efficacy was 95% and bacteriological response was 100%. No side effect was observed. From these findings, we consider that LVFX will be a useful antibacterial agent against obstetric and gynecological infections.
Cho
N
N
Department of Obstetrics and Gynecology, Showa University, Fujigaoka Hospital.
Araki
H
H
Kimura
T
T
Shimizu
A
A
Ichikawa
K
K
Fukunaga
K
K
Kunii
K
K
D000284:Administration, Oral; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D064704:Levofloxacin; D008875:Middle Aged; D015242:Ofloxacin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D010053:Ovary / Q000378:metabolism*; D014599:Uterus / Q000378:metabolism*
D064704:Levofloxacin; D015242:Ofloxacin